101 related articles for article (PubMed ID: 19922570)
1. Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting.
Senn O; Seidenberg A; Rosemann T
Addiction; 2009 Dec; 104(12):2033-8. PubMed ID: 19922570
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
3. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
4. [Prevention and treatment of hepatitis C in illicit drug users].
Sakoman S
Acta Med Croatica; 2009 Dec; 63(5):437-42. PubMed ID: 20198904
[TBL] [Abstract][Full Text] [Related]
5. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy.
Schäfer A; Wittchen HU; Backmund M; Soyka M; Gölz J; Siegert J; Schäfer M; Tretter F; Kraus MR
Addiction; 2009 Apr; 104(4):630-40. PubMed ID: 19335661
[TBL] [Abstract][Full Text] [Related]
6. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting.
Seidenberg A; Rosemann T; Senn O
BMC Infect Dis; 2013 Jan; 13():9. PubMed ID: 23298178
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
8. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
[TBL] [Abstract][Full Text] [Related]
9. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
10. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
Duburcq A; Charpak Y; Blin P; Madec L
Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
[TBL] [Abstract][Full Text] [Related]
11. Methadone maintenance treatment (MMT) in general practice or in specialized centers: profile of patients in the Swiss Canton of Vaud.
Pelet A; Doll S; Huissoud T; Resplendino J; Besson J; Favrat B
Am J Drug Alcohol Abuse; 2007; 33(5):665-74. PubMed ID: 17891659
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
Moucari R; Asselah T; Cazals-Hatem D; Voitot H; Boyer N; Ripault MP; Sobesky R; Martinot-Peignoux M; Maylin S; Nicolas-Chanoine MH; Paradis V; Vidaud M; Valla D; Bedossa P; Marcellin P
Gastroenterology; 2008 Feb; 134(2):416-23. PubMed ID: 18164296
[TBL] [Abstract][Full Text] [Related]
13. Methadone maintenance and hepatitis C virus infection among injecting drug users.
Crofts N; Nigro L; Oman K; Stevenson E; Sherman J
Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782
[TBL] [Abstract][Full Text] [Related]
14. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients.
Vigezzi P; Guglielmino L; Marzorati P; Silenzio R; De Chiara M; Corrado F; Cocchi L; Cozzolino E
J Subst Abuse Treat; 2006 Jul; 31(1):3-7. PubMed ID: 16814005
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
[TBL] [Abstract][Full Text] [Related]
16. Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
Hallinan R; Byrne A; Agho K; Dore GJ
Drug Alcohol Depend; 2007 Apr; 88(1):49-53. PubMed ID: 17067763
[TBL] [Abstract][Full Text] [Related]
17. Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?
Villar LM; de Melo MM; Calado IA; de Almeida AJ; Lampe E; Gaspar AM
J Gastroenterol Hepatol; 2009 Feb; 24(2):238-42. PubMed ID: 19215334
[TBL] [Abstract][Full Text] [Related]
18. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C.
Hsu CS; Liu CJ; Liu CH; Wang CC; Chen CL; Lai MY; Chen PJ; Kao JH; Chen DS
Liver Int; 2008 Feb; 28(2):271-7. PubMed ID: 18028320
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
20. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
Srinivas D; Mani H; Crumpler C; Van Thiel DH
Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
